Blog Archives

Capturing Choreatic Dyskinesia Over Levodopa Dose Cycle in Parkinson’s Disease

T. Mera, Michelle Burack, MD, PhD, Frank Bonsignore, MS, J. Giuffrida, PhD
16th International Congress of Parkinson’s Disease and Movement Disorders, Dublin, Ireland 2012

Read more ›



Capturing Choreatic Dyskinesia Over Levodopa Dose Cycle in Parkinson’s Disease

T. Mera, Michelle Burack, MD, PhD, Frank Bonsignore, MS, J. Giuffrida, PhD
American Academy of Neurology 64th Annual Meeting, New Orleans, LA 2012

Read more ›



PRESS RELEASE: GLNT Awarded Patent for Technology to Assess Parkinson’s Disease

VIEW PRESS RELEASE [PDF]

8MAR2012: Valley View, OH – Great Lakes NeuroTechnologies announced today that they have received allowance of claims from the U.S. Patent Office for an application covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

Read more ›



PRESS RELEASE: The University of Rochester and Great Lakes NeuroTechnologies launch new clinical study to develop ambulatory dyskinesia assessment system

VIEW PRESS RELEASE [PDF]

Cleveland, OH – August 15, 2011 – Great Lakes NeuroTechnologies’ KinetiSense motion sensor technology will be used in a clinical study to capture and quantify dyskinesias (involuntary, irregular movements) caused by Parkinson’s disease (PD) medication. PD motor symptoms including tremor and bradykinesia are typically treated with levodopa.

Read more ›



PRESS RELEASE: CLEVEMED LAUNCHES CLINICIAL STUDY MONITORING PARKINSON’S DISEASE MOTOR SYMPTOMS IN THE CLINIC AND AT HOME USING KINESIA™

VIEW PRESS RELEASE [PDF]

CLEVELAND, Ohio (January 28, 2009) – Cleveland Medical Devices Inc. (CleveMed) has launched a large scale multicenter clinical study to continue development and validation of Kinesia™, a compact wireless system for monitoring severity of Parkinson’s disease (PD) motor symptoms. Kinesia uses miniature motion sensors worn on the hand and wirelessly transmits motor symptom information to a PC.

Read more ›



Top